Philips Respironics settlement talks with the United States Department of Justice have reached an agreement in principle, closing a major chapter in the long-running investigation into the company's 2021 recall of sleep and respiratory-care devices. Philips announced the Philips DOJ settlement on Tuesday, November 3, 2026, alongside its third-quarter results, and said it had recorded a provision of 288 million euros, about 322 million dollars, to cover the proposed deal.

Key Points

• Philips Respironics reached an agreement in principle with the US Department of Justice over criminal and civil investigations linked to the recall.
• Philips booked a 288 million euro provision in the third quarter of 2026 for the proposed settlement.
• The deal is subject to final documentation, with payment expected in the first quarter of 2027.
• Philips gave no detail on whether the agreement includes an admission of wrongdoing.
• Separate proceedings, including a US state attorneys general investigation, are not covered by the provision.

What Happened

Philips said its Respironics unit had reached an agreement in principle with the Justice Department to resolve previously disclosed criminal and civil investigations related to the Respironics recall. The announcement came in the company's third-quarter results statement on November 3, 2026. Chief executive Roy Jakobs told journalists in a post-earnings call that the agreement had been reached in the last few days, according to Reuters.

Jakobs declined to describe the terms in detail. "We cannot provide details qualitatively at this point in time," he said, Reuters reported. That caution is normal at this stage: an agreement in principle is not yet a signed, final settlement, and the company said the deal remains subject to finalisation of the relevant documentation. Once that paperwork is complete, Philips expects to pay the settlement amount in the first quarter of 2027.

Background and Context

The case traces back to 2021, when Philips recalled millions of sleep and respiratory-care devices around the world. The concern centred on sound-reducing foam used in the machines, which could degrade and potentially become toxic. The recall affected people who relied on the devices for sleep apnoea and other respiratory conditions, and it triggered years of regulatory scrutiny, court cases and investigations.

Philips, the Dutch healthcare technology manufacturer, sells products ranging from toothbrushes to medical imaging systems, but the Respironics recall became one of the most consequential episodes in its recent history. Related probes and court cases followed the recall, and the company has spent years working through repairs, replacements and legal exposure. In its latest statement, Philips said it continues to make progress in resolving the consequences of the Sleep and Respiratory Care recall.

Philips Respironics Settlement

The Philips Respironics settlement matters because it addresses the federal criminal and civil investigations together, rather than leaving them as open-ended risks. For investors, the provision puts a number on the federal exposure, at least for now, and gives a timetable for payment. For patients and clinicians, the announcement is a reminder that the recall's legal aftermath is still being resolved, even as the devices themselves have long since been the subject of repair and replacement programmes.

Philips also reported a stronger underlying quarter alongside the settlement news. Reuters reported that the company beat market expectations for third-quarter core earnings, driven by higher sales and gross margin alongside productivity measures. Its adjusted earnings before interest, taxes and amortisation rose 7.2 percent to 569 million euros, about 637 million dollars, exceeding a consensus estimate of 522 million euros provided on the company's website. Philips said it slightly missed sales expectations when recall-related costs and other non-recurring effects were excluded, a detail that shows the settlement headline did not arrive in an otherwise flawless quarter.

Reactions and Quotes

Jakobs framed the Justice Department agreement as progress rather than closure. "We continue to make progress in resolving the consequences of the Sleep and Respiratory Care recall," he said in the results statement. "The Respironics agreement in principle with the US Department of Justice marks an important step in this process." The wording matters: an important step, not the final step, because other proceedings remain open.

On the earnings call, Jakobs was asked about the substance of the deal and gave little away. "We cannot provide details qualitatively at this point in time," he said, adding that the agreement in principle was reached in the last few days. The company also did not provide details on whether the agreement would include an admission of wrongdoing, Reuters reported.

Why It Matters

For American patients, the settlement is significant because the recall involved devices used every night by people with serious breathing and sleep conditions. Any suggestion that foam could degrade raised understandable alarm, and the years since have been marked by uncertainty about replacement devices, repair timelines and health risk. A federal settlement does not by itself answer every medical question, but it does reduce one layer of uncertainty: the federal investigations that have hung over the recall are now, in principle, on a path to resolution.

For the wider medical-device industry, the case is a cautionary example of how a materials problem can become a multi-year legal and financial event. A foam component, chosen to reduce sound, became the centre of a global recall, regulatory action and parallel investigations. Companies watching Philips will note both the scale of the provision and the time it took to reach even an agreement in principle, more than five years after the recall began.

What Happens Next

The next step is documentation. Philips and the Justice Department must finalise the relevant documents for the agreement in principle to become a binding settlement. If that process completes on schedule, payment is expected in the first quarter of 2027, and Philips has already built that payment into its 2026 outlook assumptions.

Separately, the state attorneys general investigation will continue. Jakobs said discussions were ongoing, but gave no timetable and booked no provision, which means any future announcement there could still move the company's financial picture. Investors will also watch whether Philips discloses more about the federal terms once documentation is final, including whether any admission of wrongdoing forms part of the deal.

Frequently Asked Questions

What did Philips announce on November 3, 2026?
Philips Respironics reached an agreement in principle with the US Department of Justice to resolve criminal and civil investigations linked to the 2021 recall.

How much is the Philips settlement provision?
Philips booked a provision of 288 million euros, about 322 million dollars, in the third quarter of 2026.

When will Philips pay the settlement?
Payment is expected in the first quarter of 2027, once the final documentation is complete.

Does the deal cover all Respironics legal cases?
No. Philips said its outlook excludes other proceedings, including an investigation by US state attorneys general, which remains ongoing.

Did Philips admit wrongdoing?
Philips did not provide details on whether the agreement includes an admission of wrongdoing, and its chief executive declined to describe the terms qualitatively.

Related coverage: Wall Street closes mixed as Nasdaq falls on tech sell-off, US stock futures slip on Election Day as Apple outlook weighs, and StatStrip glucose meter recall hits hospitals in FDA's most serious warning.